Table 1.
Demographic and clinical features of the enrolled patients.
|
Education (Y) |
MMSE |
FTD variant |
TAU protein pg/ml |
Phosphorylates TAU protein pg/ml |
Medication | |
|---|---|---|---|---|---|---|
| 1 | 13 | 24 | BV | 138 | 38 | Anti-hypertensive; Antidepressive |
| 2 | 13 | 25 | PPA | 205 | 70 | Anti-hypertensive; Antipsicotic; Cholinesterase Inhibitor; Insuline; Antiplatelet; Statins |
| 3 | 13 | 21 | BV | 1,119 | 89 | Anti-hypertensive |
| 4 | 5 | 28 | BV | 32 | 17 | Antipsicotic; Anti-hypertensive; Anxiolitic |
| 5 | 13 | 23 | BV | 586 | 71 | Antipsicotic Antidiabetic |
| 6 | 18 | 22 | PPA | 1,005 | 95 | Anti-depressive |
| 7 | 18 | 27 | PPA | 580 | 61 | Anti-hypertensive; Antiplatelet |
| 8 | 13 | 30 | BV | 363 | 84 | Anti-hypertensive; Anti-depressive Statins |
| 9 | 8 | 20 | BV | 371 | 164 | Statins Antidiabetic Antiplatelet |
| 10 | 13 | 25 | BV | 313 | 35 | Anti-hypertensive; Anti-depressive |
| 11 | 8 | 28 | PPA | 211 | 81 | Antiplatelet; Antipsicotic |
| 12 | 5 | 30 | BV | 237 | 128 | Anti-hypertensive; Anti-depressive; Statins |
| 13 | 13 | 21 | PPA | 864 | 86 | Antipsicotic |
MMSE, mini mental state examination; FTD, fronto-temporal dementia; BV, behavioral variant of FTD; PPA, primary progressive aphasia; SD, standard deviation; anti-hypertensive: nifedipine, candesartancilexetil, amlodipine, indapamide hemihydrates, hydrochlorothiazide/irbesartan, nebivolol; anti-depressive: citalopram; antipsicotic: quetiapine, promazine, haloperidol; cholinesterase inhibitor: rivastigmine; antiplatelet: cardioaspirine; statins: atorvastatin, antidiabetic: metformin; anxiolytic: hydroxyzine hydrochloride.